Zai Lab Ltd (ZLAB)
128.64
+2.25 +1.78%
NASDAQ
Sep 17, 16:00
128.22
0.00 0.00%
After-Hours: 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 76.25M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -6.14 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -524.85M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 70.58% |
| Profit Margin (Quarterly) | -442.2% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 12.27B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 138.81 |
| PE Ratio | -- |
| Price to Book Value | 7.342 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -70.02M |
| Return on Equity | Upgrade |
View All ZLAB News
News
-
WireHeadlineTime (ET)
-
Yahoo09/17 10:25
-
MT Newswires09/17 09:10
-
SA Breaking News09/16 11:42
-
MT Newswires09/16 08:16
-
Globe Newswire09/16 07:30
-
MT Newswires09/15 14:13
-
MT Newswires09/14 08:14
-
Yahoo09/14 07:30
-
Yahoo09/10 17:06
-
MT Newswires09/10 16:25
-
MT Newswires09/09 08:04
-
Yahoo09/09 07:30
-
MT Newswires09/07 11:56
-
PR Newswire08/25 08:30
-
Yahoo08/24 07:30
-
MT Newswires08/09 16:31
-
Yahoo08/09 16:30
-
Globe Newswire08/09 16:30
-
MT Newswires08/04 14:02
-
Yahoo08/04 11:53
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/15/2021 | Earnings Results | Q3 2021 Earnings Results |
| 11/15/2021 08:00 EST | Earnings Calls | Q3 2021 Earnings Call |
| 08/10/2021 | Earnings Results | Q2 2021 Earnings Results |
| 08/10/2021 08:00 EST | Earnings Calls | Q2 2021 Earnings Call |
| 06/24/2021 08:00 EST | AGM | 2020 Annual General Meeting |
| 05/10/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/10/2021 08:00 EST | Earnings Calls | Q1 2021 Earnings Call |
| 03/01/2021 | Earnings Results | Q4 2020 Earnings Results |
| 03/01/2021 08:00 EST | Earnings Calls | Q4 2020 Earnings Call |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. The company operates through the segment being Developing and commercializing proprietary therapeutics.
- URL: http://www.zailaboratory.com
- Investor Relations URL: http://www.zailaboratory.com/in1/
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Large Cap/Growth
- Next Earnings Release: Nov. 15, 2021
- Last Earnings Release: Aug. 10, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 128.64 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| CHIH | Global X MSCI China Health Care ETF | 5.06% |
| ZCH.TO | BMO China Equity ETF | 2.76% |
| KURE | KraneShares MSCI All China Hlth Care ETF | 2.63% |
| GERM | ETFMG Treatments Testing and Adv ETF | 2.49% |
| PGJ | Invesco Golden Dragon China ETF | 2.40% |
| BEXUX | Baron Emerging Markets R6 | 2.22% |
| BGLUX | Baron Global Advantage R6 | 2.19% |
| CHNA | Loncar China BioPharma ETF | 1.96% |
| FKBSX | Federated Hermes Kaufmann Small Cap B | 1.95% |
| KAUBX | Federated Hermes Kaufmann B | 1.91% |
| CNWFX | American Funds New World 529F | 1.42% |
| BGEHX | Baillie Gifford Emerging Markets Eqs 2 | 1.29% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ZLAB Tweets Stocktwits
Advertisement
